Inactive Instrument

MetaStat Inc Stock OTC Bulletin Board

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

18-06-21	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
17-08-03	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI

MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	529K 459K 428K 393K 744K 50.32M 752K 5.05M 1.97M 25.15M 1.99M 1.94M 83.34M	P/E 2017	-0.72x	P/E 2018	-2.02x
Enterprise Value	1.21M 1.05M 981K 901K 1.7M 115M 1.72M 11.57M 4.52M 57.63M 4.55M 4.45M 191M	EV / Sales 2017	-	EV / Sales 2018	329,023,519x
Free-Float	98.43%	Yield 2017 *	-	Yield 2018	-

18-06-21	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
17-08-03	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI
17-08-02	MetaStat, Inc. announced that it has received $2.57 million in funding	CI
17-06-22	MetaStat, Inc. announced that it expects to receive $7 million in funding	CI
17-06-19	MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation	CI
17-05-31	MetaStat, Inc. Appoints Paul Billings to its Board of Directors, Effective as of May 24, 2017	CI
17-05-08	MetaStat, Inc. Announces Management Changes	CI
17-05-08	MetaStat, Inc. Announces Board Changes	CI
17-04-28	MetaStat, Inc. Announces Resignation of Martin J. Driscoll from the Board of Directors	CI
17-04-06	MetaStat, Inc. Presents Supportive Data for the Role of Mena Protein Isoforms in Tumor Dissemination at the 2017 American Association of Cancer Research Annual Meeting	CI
16-12-19	MetaStat, Inc. Receives Additional State Clinical Laboratory Licenses	CI
16-12-13	MetaStat, Inc. Presents Positive Data from Two Clinical Studies of Metasite Breast at 2016 San Antonio Breast Cancer Symposium	CI
16-10-20	MetaStat, Inc. announced that it has received $2.61 million in funding	CI

Director	Title	Age	Since
Douglas A. Hamilton BRD	Director/Board Member	59	2017-05-03
Paul Billings BRD	Director/Board Member	73	2017-05-23

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.45%	-3.34%	-0.36%	+13.34%	48B
REVOLUTION MEDICINES, INC.	+6.03%	+5.22%	+420.33%	+519.87%	41.13B
IQVIA HOLDINGS INC.	-2.21%	-6.07%	+24.87%	+5.20%	37.56B
BEONE MEDICINES AG	+2.94%	-2.25%	+6.15%	+59.69%	35.91B
CELLTRION, INC.	+1.98%	+4.74%	+12.19%	+41.37%	29.86B
ASCENDIS PHARMA A/S	+0.47%	-3.87%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+0.31%	+0.72%	+32.99%	+122.25%	16.05B
EUROFINS SCIENTIFIC SE	+0.55%	+0.82%	+3.90%	+17.85%	13.76B
ICON PUBLIC LIMITED COMPANY	-0.98%	-12.98%	-4.82%	-38.09%	12.1B
Average	+0.97%	-1.81%	+61.91%	+92.68%	27.83B
Weighted average by Cap.	+1.28%	-0.93%	+82.41%	+116.66%

	2017	2018
Net sales	-	0.02 0.02 0.02 0.02 0.03 2.22 0.03 0.22 0.09 1.11 0.09 0.09 3.67
Net income	-2.94M -2.55M -2.38M -2.19M -4.14M -280M -4.18M -28.08M -10.98M -140M -11.05M -10.8M -463M	-3.18M -2.76M -2.58M -2.37M -4.47M -303M -4.52M -30.36M -11.87M -151M -11.95M -11.68M -501M
Net Debt	206K 179K 167K 153K 290K 19.63M 293K 1.97M 770K 9.81M 775K 758K 32.52M	683K 593K 553K 508K 961K 64.98M 971K 6.52M 2.55M 32.48M 2.57M 2.51M 108M

MetaStat Inc Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation: MetaStat Inc

Latest news : MetaStat Inc

Managers and Directors: MetaStat Inc

Other Biotechnology & Medical Research

Financials

Company Profile